Hem/Onc Roundup: New Triplet Combos for Breast Cancer and Melanoma, FDA Approvals, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved two new drugs, new studies assessed triplet therapies for various cancers, and more.

The addition of tucatinib to trastuzumab and capecitabine better improved overall survival and progression-free survival (primary endpoint) compared with the addition of placebo in women with human epidermal growth factor receptor 2-positive metastatic breast cancer, according to a study published in The New England Journal of Medicine.

The FDA granted accelerated approval to Padcev™ (enfortumab vedotin-ejfv) for adults with previously treated locally advanced or metastatic urothelial cancers.

The outcomes of a randomized, phase III trial showed that adding Tecentriq (atezolizumab) to Cotellic (cobimetinib) and Zelboraf (vemurafenib) successfully reduced the risk of disease progression or death in patients with previously untreated BRAF V600 mutation-positive advanced melanoma.

The FDA approved a supplemental new drug application for Xtandi® (enzalutamide) for the treatment of metastatic castration-sensitive prostate cancer.

In case you missed it, more hem/onc headlines are featured below:

• Oral Formulation of Paclitaxel Improves Breast Cancer Response Compared With IV
• A Potential Blood Cancer Vaccine Formula
• Pancreatic Cancer Treatment and Tumor Biology Differences by Race
• African Americans with Cancer at Higher Risk for Blood Clots